يعرض 1 - 20 نتائج من 71 نتيجة بحث عن '(( significantly less decrease ) OR ( significantly better decrease ))~', وقت الاستعلام: 0.30s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    Characteristics of LC patients. حسب Huriye Senay Kiziltan (22298378)

    منشور في 2025
    الموضوعات:
  11. 11
  12. 12
  13. 13
  14. 14

    Flowchart of this study. حسب Huriye Senay Kiziltan (22298378)

    منشور في 2025
    الموضوعات:
  15. 15
  16. 16

    Combination of intraperitoneal and intratumoral administration of vitamin D3 is more effective in reducing the EAC tumor volume compared to just i.p. administration: حسب Vidya G. Bettada (22208808)

    منشور في 2025
    "…Administration of cisplatin (2.5 mg/Kg) and vitamin D3 (125 µg/Kg) significantly decreased the vessel density (CD31) compared to the tumor control group.…"
  17. 17
  18. 18

    Key Resources. حسب Jeffrey Chin (22538086)

    منشور في 2025
    "…Unexpectedly, we found that Tax1bp1-deficient mice were less susceptible to <i>Mtb</i> infection, and generated reduced inflammatory cytokine responses, compared to wild-type mice; the same mutant mice exhibited decreased growth of, and inflammatory cytokine responses to, <i>Listeria monocytogenes</i>, suggesting that Tax1bp1 plays a role in host responses to multiple intracellular pathogens. …"
  19. 19

    Tax1bp1-deficiency reduces autophagy flux. حسب Jeffrey Chin (22538086)

    منشور في 2025
    "…Unexpectedly, we found that Tax1bp1-deficient mice were less susceptible to <i>Mtb</i> infection, and generated reduced inflammatory cytokine responses, compared to wild-type mice; the same mutant mice exhibited decreased growth of, and inflammatory cytokine responses to, <i>Listeria monocytogenes</i>, suggesting that Tax1bp1 plays a role in host responses to multiple intracellular pathogens. …"
  20. 20

    Study data. حسب Jie Liu (15128)

    منشور في 2025
    "…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…"